Skip Navigation

A Phase 2 Study of the MEK Inhibitor Trametinib NSC 763093 in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Brief Summary


Study Type:

II Identifier:

Study #:
CMH - ADVL1521

Start Date:
Mar 13, 2018

Full Details and Eligibility at

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below. ID: NCT03190915

View Complete Trial Details & Eligibility at